The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen
Open accessAbstract
Transferrin receptor (CD71) is involved in the cellular uptake of iron and is expressed on cells with high proliferation. It may be implicated in promoting the growth of endocrine resistant phenotypes within ER+/luminal-like breast cancer. We used a panel of in vitro cell models of acquired resistance to tamoxifen (TAMR), Faslodex (FASR) or severe oestrogen deprivation (MCF-7X) and the ER+ luminal MCF-7 parental line to determine CD71 mRNA expression and to study transferrin (Tf) effects on in vitro tumour growth and its inhibition. Furthermore, CD71 protein expression was assessed in a well-characterized series of patients with invasive breast carcinoma using tissue microarrays. Our results demonstrated a striking elevation of CD71 in all cell models of acquired resistance. Exogenous Tf significantly promoted growth in MCF-7-X and MCF-7 cells but more so in MCF-7-X; this growth was significantly reduced by Faslodex (FAS) or a phosphoinositide-3 kinase inhibitor (LY294002). Increased CD71 expression was associated with poor NPI score, tumour proliferation, basal CKs, p53, EGFR, HER2, steroid receptor negativity and shortened breast cancer specific survival (P < 0.001). On multivariate analysis, CD71 was found to be an independent prognostic factor in the ER+ cohort of patients. In conclusion, therapies of current interest in breast cancer (e.g. FAS, PI3K-inhibitors) appear able to partially impact on transferrin/CD71-promoted growth, but further investigation of this important mitogenic mechanism may assist in designing new therapeutic strategies to target highly proliferative, endocrine resistant breast cancers. CD71 appears to be a candidate marker of a subgroup of ER+/luminal-like breast cancer characterised by poor outcome and resistance to tamoxifen.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Upregulation of this highly conserved iron acquisition pathway is found in a variety of cancers, including breast and colon [90,91,92,93].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [91]
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Elston, C. W., & Ellis, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,181
Self-citationRepeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101
Sotiriou, C. P., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A. A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 2,024
Pathological prognostic factors in breast cancer
Elston, C. W. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,744
Predicting the clinical status of human breast cancer by using gene expression profiles
West, M., Blanchette, C., Dressman, H. K., Huang, E. S., Ishida, S., Spang, R., Zuzan, H., Olson, J. A., Marks, J. R., & Nevins, J. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201162998 · Cited by 1,318
The Nottingham prognostic index in primary breast cancer
Galea, M. H., Blamey, R. W., Elston, C. W., & Ellis, I. O. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01840834 · Cited by 1,078
Self-citationMcCarty, K. S., MILLER, L. S., Cox, E. B., Konrath, J. G., & McCarty, K. S. (1985) · PubMed · Cited by 1,027
Research works printed but not linked: 2
- Lanson B, Drenou B, Gueret P, Amiot L, Bernard M, Dauriac C et al (1997) Prognostic value of CD71 expression in mantle cell lymphoma. Exp Hematol 25:401
- Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi: 10.1073/pnas.191367098 · DOI
Cited by
Sorted by citations
Items 201–236 of 236
Evaluation of CD71 Expression in Acute Leukemia in Egyptian Patients
El-Sakhawy, Y. N. (2016) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v4i10.41 · Cited by 1
Immunophenotypic features of molecular subtypes of breast cancer
Чулкова, С. В., Шолохова, Е. Н., Poddubnaya, I. V., Артамонова, Е. В., Semyanikhina, A. V., Stylidi, I. S., & Tupitsyn, N. N. (2022) · Medical alphabet · doi:10.33667/2078-5631-2022-26-20-26 · Cited by 1
Чулкова, С. В., Шолохова, Е. Н., Poddubnaya, I. V., Stylidi, I. S., & Tupitsyn, N. N. (2022) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2022-21-4-50-61 · Cited by 1
Fox, J. L., Dickens, L. S., Jukes‐Jones, R., Miles, G. J., Langlais, C., Cain, K., & MacFarlane, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.25.436271 · Cited by 1
Crosstalk Between Iron Homeostasis And Nitric Oxide Signalling: Impact On Cancer Cell Viability
Ariffin, M. (2012) · Otago University Research Archive (University of Otago)
Leite, L. R. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/v3x7-ys11
The Prognostic Capability and Molecular Function of Duodenal Cytochrome B in Breast Cancer
Lemler, D. J. (2016) · OpenCommons at University of Connecticut (University of Connecticut)
Transferrin Receptor Targeted Delivery Of Sirna For Gene Therapy
Xie, Y. (2017) · Human Biology
Investigating Novel Biological Mechanisms of Head and Neck Cancers
Lenarduzzi, M. (2014) · TSpace (University of Toronto)
Fer et cancers : l’exemple du cancer du sein
Callens, C. (2019) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2019.04.018
Transferrin receptor-mediated gene delivery using functionalised gold nanoparticles.
Padayachee, J. (2018) · ResearchSpace (University of KwaZulu-Natal)
Non-hematological Malignancies in the Bone Marrow
Beham‐Schmid, C., & Schmitt-Graeff, A. H. (2020) · Essentials of diagnostic pathology · doi:10.1007/978-3-662-60309-3_4
Inactivation of MYO5B Promotes Invasion and Motility in Gastric Cancer Cells
DongXiaobing, W., Chen, C., & Dongli, F. (2012)
Breast cancer immunophenotype and its relationship with haematopoiesis
Ryabchikov, D. A., Чулкова, С. В., Shamilov, F. A., Chanturiya, N. V., Дмитриевич, Ж. С., & Tupitsyn, N. N. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.2.200958
10.腹痛を主訴に来院した卵巣成熟奇形腫の3例(第28回中国四国小児がん研究会)
財前, 善., 久米, 一., 藤井, 恒., 寺岡, 広., 西林, 洋., & 岩下, 明. (1987) · 日本小児外科学会雑誌
Maurer, V., Zarinwall, A., Wang, Z., Wundrack, S., Wundrack, N., Seleci, D. A., Helm, V., Otenko, D., Frank, C., Schaper, F., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1103948/v1
Identification and analysis of genetic and chemical modulators of iron metabolism
Hawula, Z. J. (2021) · Queensland University of Technology · doi:10.5204/thesis.eprints.225904 · Cited by 1
Chetty, R., Cooper, K., & Gown, A. M. (2016) · Cambridge University Press eBooks · doi:10.1017/9781139939508.061
Lin, H., Shi, L., Zhou, D., Chen, S., He, P., Zheng, X., Qiu, F. X., Yuan, Y., Lin, S., Li, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.17.512481
CD437 increases the iron uptake by metastatic melanoma cells
Вартанян, А. А., Khochenkova, Y. A., & Kosorukov, V. S. (2022) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2022-21-3-34-39
Understanding, Targeting, and Hijacking Autophagy
Xia, H., Xu, X., Zhou, M., Zhang, M., & Ye, L. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch6
Immunological characteristics of primary tumor and bone marrow in patients with breast cancer
Ryabchikov, D. A., Чулкова, С. В., Дмитриевич, Ж. С., Osipova, A. A., & Tupitsyn, N. N. (2023) · Medical alphabet · doi:10.33667/2078-5631-2022-31-23-27
The Roles of Iron and Ferroptosis in Human Chronic Diseases
Shi, Y., Zhang, J., Luo, K., Pan, S., Shi, H., Xiong, L., & Du, S. (2023) · Biochemistry · doi:10.5772/intechopen.108790
Arumov, A., Liyanage, P. Y., Trabolsi, A., Roberts, E. R., Li, L., Ferreira, B. C. L. B., Gao, Z., Ban, Y. J., Newsam, A. D., Taggart, M. W., et al. (2023) · doi:10.1158/0008-5472.c.6512452
Arumov, A., Liyanage, P. Y., Trabolsi, A., Roberts, E. R., Li, L., Ferreira, B. C. L. B., Gao, Z., Ban, Y. J., Newsam, A. D., Taggart, M. W., et al. (2023) · doi:10.1158/0008-5472.c.6512452.v1
Johnson, M., El-Khoueiry, A. B., Hafez, N., Lakhani, N. J., Mamdani, H. M., Rodon, J. A., Sanborn, R. E., Corbacho, J. G., Boni, V., Stroh, M., et al. (2023) · doi:10.1158/1078-0432.c.6530465
Johnson, M., El-Khoueiry, A. B., Hafez, N., Lakhani, N. J., Mamdani, H. M., Rodon, J. A., Sanborn, R. E., Corbacho, J. G., Boni, V., Stroh, M., et al. (2023) · doi:10.1158/1078-0432.c.6530465.v1
Чулкова, С. В., Шолохова, Е. Н., Poddubnaya, I. V., Гладилина, И. А., Егорова, А. В., & Stilidi, I. S. (2024) · Russian Journal of Archive of Pathology · doi:10.17116/patol20248604123
THERAPEUTIC APPLICATIONS OF NANO-SILVER IN ONCOLOGY: INSIGHTS INTO MECHANISMS
PEDNEKAR, R. S., PHALKE, D. C., Mhetre, R. L., Kulkarni, N. S., & Dhole, S. N. (2025) · Innovare Journal of Medical Sciences · doi:10.22159/ijms.2025v13i6.56452
Iron-Associated Mesenchymal Plasticity and Tumor Invasion in GlioblastomaPreprint
Petry, C., Boecke, A.-S., Mohammed, A. O., Ghariwala, N. S., Jariwala, V. D., Shhab, M. A., Buchholz, O., Vasilikos, I., Nakagawa, J. M., Vlachos, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.22.695920
A proimmunotoxin nanodrug targeting AIDS-associated non-Hodgkin lymphoma
Chen, S., Qi, T., Peng, H., Kimura, E., Zhang, X., Kranz, E. O., Cao, Z., Wang, Z., Chen, W., Ancheta, L. R., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114661
Terzi, E. M., Fujihara, K. M., Molenaars, M., Biancur, D. E., & Possemato, R. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03042-w
Ling, H.-J., Zhou, J.-L., Cao, L.-Q., Li, R., Chen, Z., & Yi, Q. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.05.005
Petry, C., Boecke, A.-S., Mohammed, A. O., Ghariwala, N. S., Jariwala, V. D., Shhab, M. A. A., Buchholz, O., Vasilikos, I., Nakagawa, J. M., Vlachos, A., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag220
Introduction to Nanomedical drug delivery for lung cancer
Gupta, J., Singh, I., Chauhan, S. B., Nirbhavane, P., & Sharma, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44585-9.00013-5
Metadata
- Authors
- Habashy, H. O., Powe, D. G., Staka, C. M., Rakha, E. A., Ball, G., Green, A. R., Aleskandarany, M., Paish, E. C., Douglas Macmillan, R., Nicholson, R. I., Ellis, I. O., & Gee, J. M. W.
- Affiliations
- University of Nottingham (GB)
- Cardiff University (GB)
- Nottingham Trent University (GB)
- Corresponding author
- Ellis, Ian O.
- ORCID
- Venue
- Breast Cancer Research and Treatment
- Published
- 2009-02-24
- Volume
- 119
- Issue
- 2
- Pages
- 283-293
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2092206294
- Cited by
- 236
- References
- 44
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 10 · 2023: 20 · 2022: 15 · 2021: 24 · 2020: 19 · 2019: 26 · 2018: 11 · 2017: 20 · 2016: 17 · 2015: 8 · 2014: 10 · 2013: 8 · 2012: 13
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Nottingham Trent University's Institutional Repository (Nottingham Trent Repository) (submittedVersion)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- transferrin receptor, breast cancer, tamoxifen resistance, endocrine therapy resistance, estrogen receptor-positive breast cancer, prognostic factors, transferrin, PI3K inhibitors, LY294002, fulvestrant, MCF-7 cells, tumour proliferation, breast cancer-specific survival, HER2, EGFR, p53
- MeSH terms
- Fulvestrant, Phosphoinositide-3 Kinase Inhibitors, Adult, Breast Neoplasms, Carcinoma, Chromones, Estradiol, Female, Flavonoids, Humans, Immunohistochemistry, Middle Aged, Morpholines, Neoplasm Invasiveness, Predictive Value of Tests, Receptors, Estrogen, Receptors, Transferrin, Retrospective Studies, RNA, Messenger, Tamoxifen, Time Factors, Transferrin, Biomarkers, Tumor, Antigens, CD, Gene Expression Regulation, Neoplastic, Proportional Hazards Models, Treatment Outcome, Risk Assessment, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Reverse Transcriptase Polymerase Chain Reaction, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Tissue Array Analysis, Protein Kinase Inhibitors, Cell Proliferation, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
